S6 Kinase 2 Deficiency Improves Glucose Disposal in Mice Fed a High Fat Diet

Kristin M Taylor1*, Jeffrey Bajko1, Mario S Cabrera1, Cliff Kremer1, Birgit Meyer-Puttlitz2, Anke M Schulte2, Seng H Cheng1, Ronald K Scheule1 and Rodney J Moreland1*

1Genzyme, a Sanofi Company, Framingham, USA
2Sanofi Corporation, Frankfurt, Germany

Abstract

The mammalian target of rapamycin complex 1 (mTORC1) regulates insulin-mediated glucose metabolism, cell proliferation, the oxidative branch of the pentose phosphate pathway, de novo lipogenesis, and autophagy. Ribosomal S6 kinase 1 (S6K1) and 2 (S6K2) are downstream effectors of mTORC1. To characterize the role of S6K2 in insulin-mediated metabolism, the response of S6K2 deficient mice (S6K2−/−) to a glucose challenge was compared to that of wild-type (C57BL/6) and diabetes resistant strains (BALB/c and A/J) after 35 weeks on a high fat diet (HFD). Although S6K2−/− mice fed a HFD gained as much weight as the wild-type C57BL/6 control mice, unlike the wild-type mice they remained glucose tolerant, insulin sensitive, and had lower basal blood glucose levels. Moreover, unlike S6K1 deficient mice, S6K2−/− mice have increased basal plasma insulin levels and increased β-cell mass compared to C57BL/6, BALB/c, and A/J mice. Administration of insulin to S6K2−/− and C57BL/6 mice fed a Standard Diet (SD) resulted in phosphorylation of Ser307 on skeletal muscle Insulin Receptor Substrate 1 (IRS-1); however, when both strains were fed a HFD, phosphorylation of IRS-1 Ser307 was maintained in S6K2−/− mice but inhibited in C57BL/6 mice. Taken together, these results suggest that S6K2 inhibition may represent a strategy for treating type 2 diabetes.

Keywords: Glucose tolerance test; Insulin tolerance test; β-cell mass; S6K2; Diabetes

Introduction

The mammalian Target of Rapamycin (mTOR) senses cellular energy and can either promote cell growth and proliferation or induce catabolism and autophagy. mTOR is a conserved serine/threonine kinase that exists in several distinct multi-protein complexes such as mTORC1 (containing raptor) and mTORC2 (containing rictor) [1-3]. mTORC1 regulates autophagy and metabolic pathways, including glycolysis, de novo lipid biosynthesis, and the oxidative arm of the pentose phosphate pathway [4]. An additional mTORC1-regulated pathway was revealed when we treated Pompe mice with rapamycin and observed the abatement of lysosomal glycogen accumulation in skeletal muscle [5]. Hence, a better understanding of how mTORC1 interfaces with these diverse metabolic pathways in different tissues may lead to new therapies to treat Pompe disease as well as other metabolic disorders such as type 2 diabetes.

The most characterized substrate of mTORC1 is ribosomal S6 kinase 1 (S6K1). S6K1 deficient mice on a High Fat Diet (HFD) exhibit improved insulin sensitivity and are protected against obesity when compared to HFD-fed wild-type controls [6]. Hence, inhibiting S6K1 is currently being considered as a potential strategy to treat type 2 diabetes [7]. However, S6K1 inhibition has several potential untoward effects. For example, S6K1 deficient mice on a Standard Diet (SD) are glucose intolerant, hypoinsulinemic, and have reduced β-cell mass [8].

Less is known about ribosomal S6 kinase 2 (S6K2), another mTORC1 substrate. S6K2 shares 84% amino acid identity with S6K1 in the kinase domain and less than 60% homology in the N- and C-terminal regions [9]. A recent report demonstrated that unlike S6K1−/− mice, mice deficient in both S6K1 and S6K2 had normal glucose tolerance on SD and improved glucose tolerance on HFD when compared to wild-type mice [10]. Based on these results, we asked whether a deficiency in S6K2 alone might improve glucose tolerance on a HFD and thereby avoid the negative effects associated with S6K1 deficiency.

The aim of this study was to assess glucose tolerance and insulin sensitivity in S6K2−/− mice and compare the responses to diabetes susceptible wild-type (C57BL/6) mice and diabetes resistant strains (BALB/c, A/J) when placed on a SD or HFD [11]. We demonstrated that S6K2−/− mice on SD have higher basal plasma insulin levels than C57BL/6, BALB/c and A/J mice. On a HFD, S6K2−/− mice exhibited improved glucose tolerance and insulin sensitivity compared to wild-type C57BL/6 mice. The results of these studies support the notion that inhibiting S6K2 may represent a viable approach for treating type 2 diabetes.

Materials and Methods

Materials

ELISA kits (Total IRS-1, IRS-1 phospho Ser307, Total IRβ, IRβ phospho panTyr) were obtained from Cell Signaling (Beverly, MA). Adiponectin, insulin, and leptin ELISA kits were from EMD Millipore (Billerica, MA). BCA kit for protein determinations was from Pierce (Rockford, Ill). Humulin N was obtained from Eli Lilly (Indianapolis, IN). Glucose was obtained from Sigma (St. Louis, MO).

Animal studies

Animal experiments were conducted in accordance with Genzyme’s...
IACUC committee and the Guide for the Care and Use of Laboratory Animals (U.S. Department of Health and Human Services, NIH Publication no. 86-23).

Wild-type C57BL/6, A/J, and Balb/c mice were obtained from The Jackson Laboratory (Bar Harbor, ME). S6K2 knockout mice (S6K2-/-) were obtained from George Thomas and the Friedrich Miescher Institute for Biomedical Research (Basel, Switzerland) [12]. Picolab rodent diet 20 (5053) was obtained from Lab Diet (St. Louis, MO) and fed ad libitum as standard diet (SD). Rodent diet with 60% kcal from fat (D12492) was obtained from Research Diets (New Brunswick, NJ) and fed ad libitum as High Fat Diet (HFD).

Serum chemistries

Blood was collected via retro-orbital puncture into serum separator tubes. Cholesterol, glucose, LDH and triglycerides were analyzed with test kits from Randox using their Rx Daytona (Kearneysville, West Virginia) clinical chemistry analyzer. Serum ketone levels were analyzed using the Wako Total Ketone Body assay kit (415-73301, 411-73401) according to the manufacturer’s instructions (Richmond, VA).

Glucose tolerance tests

Glucose Tolerance Tests (GTTs) were performed on groups (n=7) of C57BL/6 and S6K2-/- mice after 31-35 weeks on HFD or SD. Mice were fasted for 6 h before oral glucose gavage (2 g/kg). Blood glucose levels were measured prior to gavage (time zero) and 30, 60 and 120 min following oral gavage [13].

Insulin tolerance tests

Insulin Tolerance Tests (ITTs) were performed on groups (n=15) of C57BL/6 and S6K2-/- mice after 30-34 weeks on HFD or SD. Mice were fasted for 6 h followed by intraperitoneal insulin injections (0.75 U/kg). Blood glucose levels were measured prior to insulin injection (time zero) and 30, 60 and 120 min following insulin injection.

Preparation of tissue homogenates

Tissue collection and protein determination by BCA were performed as previously described [14].

Pancreatic collection and morphometric analysis of beta cells

Pancreatic tissue was collected from age matched C57BL/6, S6K2-/-, BALB/c, and A/J mice. The tissues were fixed for 4 days in 10% neutral buffered formalin and embedded in paraffin, using standard protocols. The paraffin blocks were cut into 5 to 10 sets of 10 serial sections (4 µm thickness). Each set was separated by 200 µm. One tissue section from each set was deparaffinized by heat. Insulin antigen retrieval was performed by heating the samples at 95˚C for 28 min in CCI1 buffer from Ventana (Sunnyvale, CA) followed by incubation for 60 min at 37˚C with a primary anti-insulin antibody from DAKO (Carpinteria, CA). Secondary antibody incubation was performed with biotinylated goat anti-guinea pig antibody from Rockland (Gilbertsville, PA) for 16 min at 37˚C. Sections were then incubated with the DAB Map streptavidin-biotin peroxidase detection system from Ventana (Sunnyvale, CA), counterstained with hematoxylin, and mounted with mounting media from Sakura (Torrance, CA). High-resolution whole slide images were captured with the Aperio ScanScope XT (Vista, CA) and the Aperio deconvolution algorithm was used to determine the total stained insulin positive area and the total tissue area. The total insulin positive area was used as a surrogate for β-cell mass. Hence, β-cell mass was calculated as the percentage of insulin positive stained area relative to the total assessed pancreas area expressed as means ± SEM for each group (C57BL/6 HFD n=8, C57BL/6 SD n=10, S6K2-/- HFD n=6, S6K2-/- SD n=7, BALB/c HFD n=7, A/J HFD n=7) in one experiment.

Statistical analysis

All of the data are expressed as the mean ± SEM of two independent experiments. Data were analyzed by one-way ANOVA with Newman-Keuls comparing indicated treatment groups; *, P<0.05 **P<0.01 ***,
P<0.001 A probability value of P<0.05 was considered to be statistically different.

Results

Expression and Phosphorylation of the insulin receptor beta Subunit (IRβ) and Insulin Receptor Substrate 1 (IRS-1) in S6K2-/- mice on a SD or HFD

The mTOR pathway is known to regulate the level of IRS-1. For example, over activation of the pathway can cause depletion of IRS-1 protein levels [15]. Conversely, inactivation of mTOR in muscle robustly increases IRS-1 levels [16]. As S6K2 is downstream of the mTORC1 signaling pathway, we asked whether a reduction in its levels would affect the basal levels of IRβ and IRS-1. The levels of IRβ and IRS-1 in liver, triceps, quadriceps, and adipose tissue in wild-type C57BL/6 and S6K2-/- (n=8) mice regardless of whether they were fed a SD or HFD for 31 weeks were found to be similar (Figure 1A and B). This result suggests that S6K2 is not involved in the previously reported mTORC1 regulation of IRS-1 protein levels.

Stimulation of the insulin signaling pathway leads to the phosphorylation of IRβ and IRS-1 [17]. To evaluate the roles of diet and S6K2 on the phosphorylation of these two components of the pathway, we assayed the phosphorylation status of IRβ (panTyr) and IRS-1 (phosSer307) in triceps after intravenous insulin administration. In both wild-type and S6K2-/- mice (n = 8) fed either a SD or HFD, activation of the pathway with insulin caused an increase in IRβ phosphorylation, P <0.001 (Figure 1C). On a SD, provision of insulin induced a similar extent of IRS-1 phosphorylation in both wild-type and S6K2-/- mice, P<0.01 (Figure 1D). However, wild-type C57BL/6 mice that had been placed on a HFD exhibited reduced insulin-mediated phosphorylation of IRS-1, suggesting an impairment of the pathway. Interestingly, this component of the pathway in S6K2-/- mice on the same HFD remained sensitive to insulin-mediated phosphorylation, P<0.001 (Figure 1D).

S6K2-/- Mice on a HFD exhibit improved glucose disposal and insulin sensitivity

Starting at 10 weeks of age, S6K2-/- and wild-type C57BL/6 mice (n=7) were placed on either a SD or HFD for 31 weeks. At the end of the study period, GTTs of wild-type mice that had been fed a HFD demonstrated qualitatively (Figure 2A) and quantitatively, P<0.001 (Figure 2B) a reduced ability to dispose glucose when compared to their age-matched counterparts on a SD. These assays also demonstrated that glucose disposal in S6K2-/- mice on a SD was similar to that of wild-type mice and that this ability was unaffected by a HFD (Figures 2A and B). Hence, S62K-/- mice would appear to be protected from developing diabetes.

On a SD, the basal insulin levels of S6K2-/- mice were determined to be higher than those of age-matched wild-type C57BL/6 mice, P<0.01 (Figure 2C and D). After 31 weeks on a HFD, the basal insulin levels of S6K2-/- mice remained similarly elevated. However, when placed on a HFD the basal insulin levels in wild-type mice increased to those observed in the S6K2-/- mice (Figure 2C and D). As the insulin levels of both S6K2-/- and wild-type mice were similar on a HFD, it could be surmised that the improved glucose disposal noted in S6K2-/- mice compared to wild-type mice on a HFD (Figure 2A and B) was not due to differences in insulin levels. Rather, the results imply that insulin signaling remained more sensitive to insulin in the S6K2-/- mice than in wild-type mice.

To assess the insulin sensitivity of S6K2-/- and wild-type C57BL/6 mice (n=15) further, insulin was administered following a 6 h fast to mice that had been fed either a SD or HFD for 31 weeks. It should be noted that

Figure 2: Glucose tolerance test in C57BL/6 and S6K2-/- mice.
A, GTTs were performed on the mice described in the legend to Fig. 1. Groups (n=7) of C57BL/6 and S6K2-/- mice were fasted for 6 h and then administered glucose by oral gavage (2g/kg). Blood glucose levels were measured prior to oral gavage (time zero) and 30, 60 and 120 min following treatment. B, area under the curve (AUC) measurements performed on groups shown in A. C and D, blood insulin levels were measured prior to oral gavage of glucose (time zero) and 30, 60 and 120 mins following treatment. **P<0.01, ***P<0.001.
prior to insulin administration, S6K2-/- mice (on either diet) had lower blood glucose levels than wild-type mice (Figure 3A and B). This was likely due to the elevated basal insulin levels in S6K2-/- mice as described in Fig. 2C and D. As expected, wild-type mice on a HFD were found to be less responsive to insulin than the corresponding cohort fed a SD, and exhibited an impaired ability to dispose of circulating glucose, \( P<0.001 \) (Figure 3A and B). Interestingly, S6K2-/- mice placed on either a SD or a HFD remained sensitive to insulin, and exhibited an ability to dispose of glucose similar to that of wild-type mice on a SD (Figure 3A and B).

Comparison of insulin responsiveness in S6K2-/- mice and diabetes resistant mouse strains

It has been reported that unlike C57BL/6 mice, BALB/c and A/J

---

Figure 3: Insulin tolerance test in C57BL/6 and S6K2-/- mice.
A, ITTs were performed on the mice described in the legend to Fig. 1. Groups (n=15) of mice indicated were fasted for 6 h before being injected intraperitoneally with insulin (0.75 U/kg). Blood glucose levels were measured prior to insulin injection (time zero) and 30, 60 and 120 min following insulin administration. B, Area under the Curve (AUC) measurements performed on groups shown in A. ***\( P<0.001 \).

---

Figure 4: Glucose disposal in C57BL/6 and S6K2-/- mice compared to diabetes resistant mice, BALB/c and A/J.
A, bodyweights of indicated strains after 35 weeks on HFD. B, GTTs were performed as described in Figure 2 legend on groups (n=8) of indicated strains after 34 weeks on HFD. C, area under the curve (AUC) measurements performed on groups shown in B. D, ITTs were performed as described in Figure 3 legend after 35 weeks on HFD. E, Area under the Curve (AUC) measurements performed on groups shown in D. ***\( P<0.001 \).
mice are resistant to developing diabetes when fed a HFD. The insulin responsiveness of S6K2-/- mice was compared to that of these diabetes resistant strains. Groups (n=8) from all strains were fed a HFD for 35 weeks starting at 10 weeks of age. The C57BL/6 and S6K2-/- mice became obese while the BALB/c and A/J mice remained non-obese (Figure 4A). As expected, GTTs and ITTs of animals at the end of the study period demonstrated that C57BL/6 mice became glucose intolerant and insulin insensitive (Figure 4B-D). Surprisingly, although obese, the S6K2-/- mice exhibited better glucose disposal characteristics than C57BL/6 (P<0.001) and A/J mice and were similar to that of BALB/c mice (Figure 4B-E). Hence, in terms of insulin responsiveness, the S6K2-/- mice on a HFD would appear to be similar to the diabetes resistant strains A/J and BALB/c. Serum from S6K2-/- mice on a HFD was also collected under fed and fasted conditions and the resulting serum chemistry profiles compared to those of BALB/c, A/J, and C57BL/6 mice (Tables 1-4). It has been reported previously that the total ketones in S6K2-/- mice were ~2 fold higher in the fed state and ~1.4 fold higher in the fasted state compared to those of BALB/c, A/J, and C57BL/6 mice (Tables 1-4). It was previously reported that S6K1-/- mice fed ad libitum had cholesterol levels of 106.0 ± 10.2 mg/dl (Table 1) and 117.0 ± 8.6 mg/dl when fasted for 16 h (Table 2). These levels were higher than those of the other strains, but were still within what is considered the normal range, viz., 50-120 mg/dl [19]. When placed on a HFD the cholesterol levels in the obese strains (wild-type C57BL/6 and S6K2-/- mice) exceeded the normal range to a similar extent (Table 4).

It is noteworthy that unlike S6K1-/- mice that are hypoinsulinemic, S6K2-/- mice on a SD have higher insulin levels than wild-type C57BL/6 (P<0.001), BALB/c and A/J mice (Table 2; Table 4, 2 fold higher for S6K2-/- mice in 16 h and Figure 2C subjected to a HFD for 40 weeks) [8]. After being placed on a HFD for 40 weeks, insulin levels in wild-type C57BL/6 mice (that had been fasted for 16 h) were 2-fold higher than those of S6K2-/- mice, yet the S6K2-/- mice had lower blood glucose levels (Table 4). This result suggests that S6K2-/- mice have greater insulin sensitivity. It was previously reported that S6K1-/- mice have reduced β-cell mass compared to wild-type mice [8], and S6K1-/- mice fed a HFD have 10 fold lower insulin levels compared to wild-type mice [6]; therefore, we assessed the β-cell mass, which is defined as the percentage of the pancreatic tissue that stained positive for insulin, in 5 to 10 sections of pancreas from C57BL/6, BALB/c, A/J, and S6K2-/- mice (n=6-10) that were fed a HFD, starting at 10 weeks of age for 44 weeks or remained on SD for 54 weeks. Representative anti-insulin stained images for each strain are shown in Figure 5A-F. As shown in Figure 5G and H, S6K2-/- mice have a 2.5 fold higher β-cell mass compared to wild-type C57BL/6 independent of diet. The mean insulin positive stained area in the pancreas for each strain on HFD was as follows: 3.3% for S6K2-/- mice, 1.2% for C57BL/6, 0.9% for A/J, and 0.8% for BALB/c and on SD was: 2.9% for S6K2-/- mice and 0.95% for C57BL/6. This is consistent with the higher insulin levels observed in S6K2-/- mice shown in Tables 3 and 4.

The observed increase in insulin positive β-cell area was unexpected because inhibition of the mTORC1 pathway with rapamycin or S6K1 deficiency results in a reduction in β-cell mass and β-cell size (see “Discussion”). The novel observation that S6K2 deficiency increases β-cell mass provides an additional argument for the inhibition of S6K2 as an approach to treat type 2 diabetes.

**Discussion**

It is well established that insulin signaling is mediated through the mTOR pathway [1-3]. Numerous cell culture studies have shown that hyperactivation of mTORC1 induces insulin resistance, and inhibition of mTORC1 with rapamycin restores insulin signaling [15,20]. The roles of mTORC1 in whole animal metabolism have been more difficult to assess because a knockout of any component of mTORC1 is embryonic lethal [21-23].

---

### Table 1: Serum chemistries of C57BL/6, BALB/c, A/J, and S6K2-/- mice at 8 weeks of age fed SD. Mice were fed ad libitum prior to serum collection.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C57BL/6J</th>
<th>BALB/c</th>
<th>A/J</th>
<th>S6K2-/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ketones, μmol/l</td>
<td>254.5 ± 20.3</td>
<td>221.7 ± 16.5</td>
<td>347.1 ± 15.2</td>
<td>280.2 ± 39.3</td>
</tr>
<tr>
<td>Leptin, ng/ml</td>
<td>1.87 ± 0.26</td>
<td>1.88 ± 0.27</td>
<td>3.61 ± 0.46</td>
<td>3.36 ± 0.83</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>279.3 ± 10.3</td>
<td>238.8 ± 10.4</td>
<td>227.3 ± 10.1</td>
<td>244.4 ± 16.8</td>
</tr>
<tr>
<td>Cholesterol, mg/dl</td>
<td>78.1 ± 2.7</td>
<td>83.5 ± 1.4</td>
<td>86.9 ± 1.8</td>
<td>106.0 ± 10.2</td>
</tr>
<tr>
<td>LDH, U/L</td>
<td>171.0 ± 13.1</td>
<td>169.5 ± 12.2</td>
<td>341.0 ± 23.4</td>
<td>146.4 ± 4.9</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>130.7 ± 17.2</td>
<td>114.9 ± 8.6</td>
<td>125.5 ± 7.6</td>
<td>112.6 ± 19.6</td>
</tr>
</tbody>
</table>

Each value represents means ± S.E.M from groups of 8 mice. **P<0.001 between C57BL/6 and S6K2-/- mice**

---

### Table 2: Serum chemistries of C57BL/6, BALB/c, A/J, and S6K2-/- mice at 51 weeks of age fed SD for 10 weeks followed by HFD for 41 weeks. Mice were fasted for 16 h prior to collection of serum.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C57BL/6J</th>
<th>BALB/c</th>
<th>A/J</th>
<th>S6K2-/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ketones, μmol/l</td>
<td>1684 ± 167</td>
<td>1251 ± 206</td>
<td>1555 ± 262</td>
<td>1572 ± 284</td>
</tr>
<tr>
<td>Insulin, nm/g</td>
<td>0.21 ± 0.02</td>
<td>0.11 ± 0.02</td>
<td>0.16 ± 0.02</td>
<td>0.49 ± 0.14</td>
</tr>
<tr>
<td>Adiponectin, µg/ml</td>
<td>9.46 ± 0.54</td>
<td>6.54 ± 0.45</td>
<td>7.12 ± 0.57</td>
<td>10.7 ± 0.87</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>1784 ± 14.4</td>
<td>1621 ± 13.1</td>
<td>1871 ± 10.5</td>
<td>1680 ± 36.9</td>
</tr>
<tr>
<td>Cholesterol, mg/dl</td>
<td>83.7 ± 1.5</td>
<td>87.5 ± 4.3</td>
<td>66.4 ± 2.5</td>
<td>117.0 ± 8.6</td>
</tr>
<tr>
<td>LDH, U/L</td>
<td>162.8 ± 25.9</td>
<td>235.4 ± 52.6</td>
<td>254.0 ± 24.6</td>
<td>128.4 ± 15.8</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>68.4 ± 2.0</td>
<td>49.3 ± 3.9</td>
<td>62.8 ± 2.8</td>
<td>78.8 ± 11.3</td>
</tr>
</tbody>
</table>

Each value represents means ± S.E.M from groups of 8 mice. **P<0.001 between C57BL/6 and S6K2-/- mice**

---

### Table 3: Serum chemistries of C57BL/6, BALB/c, A/J, and S6K2-/- mice at 5 weeks of age fed SD for 10 weeks followed by HFD for 40 weeks. Mice were fed ad libitum prior to collection of serum.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>C57BL/6J</th>
<th>BALB/c</th>
<th>A/J</th>
<th>S6K2-/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptin, ng/ml</td>
<td>67.3 ± 6.2</td>
<td>7.8 ± 1.2</td>
<td>15.5 ± 2.1</td>
<td>35.7 ± 6.2</td>
</tr>
<tr>
<td>Glucose, mg/dl</td>
<td>252.9 ± 14.1</td>
<td>231.9 ± 12.0</td>
<td>200.0 ± 7.1</td>
<td>169.0 ± 15.5</td>
</tr>
<tr>
<td>Cholesterol, mg/dl</td>
<td>257.9 ± 8.6</td>
<td>144.4 ± 5.1</td>
<td>140.7 ± 4.0</td>
<td>223.0 ± 23.7</td>
</tr>
<tr>
<td>LDH, U/L</td>
<td>937.9 ± 114.7</td>
<td>391.4 ± 36.8</td>
<td>455.7 ± 42.3</td>
<td>816.0 ± 103.1</td>
</tr>
<tr>
<td>Triglycerides, mg/dl</td>
<td>113.6 ± 13.4</td>
<td>126.3 ± 13.5</td>
<td>141.4 ± 18.9</td>
<td>143.0 ± 21.9</td>
</tr>
</tbody>
</table>

Each value represents means ± S.E.M from groups of 8 mice. **P<0.001 between C57BL/6 and S6K2-/- mice**
While tissue-specific inhibition of mTORC1 in adipose tissue improves glucose tolerance in mice, global inhibition of mTORC1 with rapamycin impairs glucose tolerance in rodents and humans [24-26]. The disparity in these results is likely because rapamycin is toxic to pancreatic β-cells, causing a reduction in β-cell mass and consequently lower glucose-stimulated insulin secretion [25,26]. This β-cell toxicity is possibly due to inhibition of the downstream mTORC1 effector S6K1, because S6K1−/− mice also have reduced β-cell mass, are hypoinsulinemic, and glucose intolerant [8].

Given the deleterious consequences associated with S6K1 deficiency, it was unexpected that a double knockout of S6K1 and S6K2 reversed the glucose intolerance observed in the S6K1 knockout alone [10]. This observation, combined with the finding that obese ob/ob mice have markedly elevated S6K2 activity, suggested to us that specifically inhibiting S6K2 alone might prove beneficial in type 2 diabetes and potentially avoid the deleterious effects associated with S6K1 inhibition [18].

This report demonstrates that S6K2 deficient mice have a 2.5 fold increase in β-cell mass compared to wild-type C57BL/6 mice, which is independent of diet. The increase in β-cell mass supports the higher insulin levels observed in the S6K2−/− mice fed SD. In contrast, on a HFD S6K2−/− mice have similar insulin levels compared to wild type mice but demonstrate improved glucose tolerance and insulin sensitivity. Hence, a deficiency of S6K2 would appear to confer some measure of resistance to developing diabetes.

Another novel observation noted from the studies here was that
insulin-mediated phosphorylation of IRS-1 Ser307 was maintained in S6K2-/- mice but reduced in wild-type C57BL/6 mice on a HFD. The significance of Ser307 phosphorylation on IRS-1 in vivo has been tested directly in knock-in mice in which Ser307 was replaced with an alanine residue to prevent its phosphorylation [27]. These S307A mice were mildly diabetic on SD, but when fed a HFD they developed more severe insulin resistance and impaired muscle insulin signaling. Reduced phosphorylation of Ser307 has also been reported in tissues from diabetic patients compared to non-diabetic patients [17]. However, how S6K2 influences the phosphorylation state of Ser307 remains unclear. Several kinases have been reported to phosphorylate Ser307, including JNK1, IKKβ, S6K1, mTOR, and PKCβ [28]. Future studies to define the relationship of S6K2 to these kinases should prove to be informative. It remains possible that the increased phosphorylation of IRS-1 Ser307 in S6K2-/- mice on a HFD is an associated phenomenon that does not contribute directly to the observed improvement in glucose disposal. Phosphomimetic mutation of IRS-1 serine 307 to aspartic acid (S307D) has also been studied in cell-based assays [29]. The results suggest that this site does not contribute substantially to insulin resistance. However, this single phosphomimetic mutation will have to be evaluated in knock-in mice fed SD and HFD before any final conclusions can be drawn.

Conclusions

In summary, the results of this study suggest that it is possible to manipulate the mTORC1 pathway to improve glucose tolerance without reducing insulin levels or β-cell mass. Indeed, inhibition of S6K2 specifically may represent a viable strategy for intervention in type 2 diabetes.

Acknowledgments

We thank Jennifer Johnson, Michelle Searles, Elizabeth Meyers, William Weber, and members of Genzyme’s Department of Comparative Medicine for their technical assistance and valuable input.

References


